scholarly journals Medical Cannabinoids for Cancer Cachexia: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
Jing Wang ◽  
Yanling Wang ◽  
Mengting Tong ◽  
Hongming Pan ◽  
Da Li
Keyword(s):  
Quality Of Life ◽  
Cancer Patients ◽  
Cancer Cachexia ◽  
Meta Analysis ◽  
Life Quality ◽  
Cochrane Library ◽  
Cochrane Central Register ◽  
Negative Effects ◽  
Central Register

Objectives. Cancer cachexia (CCA) is an intractable and ineffective metabolic syndrome that attacks 50–80% of cancer patients. It reduces patient’s life quality, affects the efficacy of treatment, and then increases their mortality; however, there are no established therapeutic strategies for CCA in the world. In this study, we assess the positive and negative effects of cannabinoid in the treatment of CCA. Methods. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Web of Science, and PubMed up to December 2017. Results. Of the 256 screened studies, three studies with a total of 592 participants were included. Compared with placebo, cannabinoid increased the appetite (MD 0.27, 95% CI -0.51 to 1.04; n= 3) but failed to improve the overall quality of life (QOL; MD -12.39, 95% CI [-24.21 to -0.57; n = 2), and a total of 441 patients had 607 adverse events (AEs; 496 in the cannabinoid group and 111 in the placebo group). Conclusions. Our analysis showed cannabinoid is effective in increasing appetite in cancer patients. However, it declines the quality of life, which may be due to the side effects of cannabinoid.

scholarly journals The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis

2016 ◽  
Vol 47 (3) ◽  
pp. 414-425 ◽  
Author(s):  
K. Kamenov ◽  
C. Twomey ◽  
M. Cabello ◽  
A. M. Prina ◽  
J. L. Ayuso-Mateos
Keyword(s):  
Quality Of Life ◽  
Depressive Disorders ◽  
Meta Analysis ◽  
Combined Treatment ◽  
Effect Sizes ◽  
Controlled Trials ◽  
Depression Symptom ◽  
Cochrane Central Register ◽  
Central Register

BackgroundThere is growing recognition of the importance of both functioning and quality of life (QoL) outcomes in the treatment of depressive disorders, but the meta-analytic evidence is scarce. The objective of this meta-analysis of randomized controlled trials (RCTs) was to determine the absolute and relative effects of psychotherapy, pharmacotherapy and their combination on functioning and QoL in patients with depression.MethodOne hundred and fifty-three outcome trials involving 29 879 participants with depressive disorders were identified through database searches in Pubmed, PsycINFO and the Cochrane Central Register of Controlled Trials.ResultsCompared to control conditions, psychotherapy and pharmacotherapy yielded small to moderate effect sizes for functioning and QoL, ranging from g = 0.31 to g = 0.43. When compared directly, initial analysis yielded no evidence that one of them was superior. After adjusting for publication bias, psychotherapy was more efficacious than pharmacotherapy (g = 0.21) for QoL. The combination of psychotherapy and medication performed significantly better for both outcomes compared to each treatment alone yielding small effect sizes (g = 0.32 to g = 0.39). Both interventions improved depression symptom severity more than functioning and QoL.ConclusionDespite the small number of comparative trials for some of the analyses, this study reveals that combined treatment is superior, but psychotherapy and pharmacotherapy alone are also efficacious for improving functioning and QoL. The overall relatively modest effects suggest that future tailoring of therapies could be warranted to better meet the needs of individuals with functioning and QoL problems.

scholarly journals The impact of informing diagnosis on quality of life in patients with cancer: A systematic review and meta-analysis

2020 ◽  
Author(s):  
Miao Wan ◽  
Xianggui Luo ◽  
Louis.B NDZANA MVOGO ◽  
Juan Wang ◽  
Chen Chang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Cognitive Activity ◽  
Biomedical Literature ◽  
Cochrane Central Register ◽  
Patients With Cancer ◽  
General Quality ◽  
The Impact

Abstract Objective To assess the impact of informing diagnosis and disease status on the quality of life in patients with cancer Method We searched the follow databases, Pubmed, CENTRAL(Cochrane Central Register of Controlled Trials), PsycINFO, WEB OF SCIENCE, Embase, CBM (Chinese Biomedical Literature database), WANFANG database (Chinese Medicine Premier), and CNKI (China National Knowledge Infrastructure). And the terms used are as follows: neoplasm, cancer, tumour, tumor, carcinoma, disclosure, truth telling, breaking bad news, knowledge, knowing, awareness, quality of life, QOL. Pairs of reviewers independently screened documents and extracted the data. Meta-analysis was conducted by Revman 5.0 software. Results There were 11740 records retrieved from databases and 23 studies were included finally. Meta-analysis of informed and uniformed cancer patients revealed no differences in both the general quality of life and symptoms of fatigue, pain, dyspnea, insomnia, appetite loss and diarrhea (P>0.05). Additionally, no difference in physical function, role function, cognitive activity and emotional function between the above 2 groups(P>0.05) were found. On the vitality area, the patients who were totally informed about their diagnosis had higher vitality than the uniformed patients. However, patients aware about their illnesses seemed to get lower scores in social function. Between the partly informed of the diagnosis and uninformed cancer patients, there were no differences in general quality of life, function domains and disease-related symptoms (P>0.05). Conclusion Informing the cancer patients their diagnosis may not have a bad effect on their quality of life. PROSPERO registration number CRD42017060073.

scholarly journals The impact of informing diagnosis on quality of life in patients with cancer: A systematic review and meta-analysis

2020 ◽  
Author(s):  
Miao Wan ◽  
Xianggui Luo ◽  
Juan Wang ◽  
Louis.B NDZANA MVOGO ◽  
Chen Chang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Cognitive Activity ◽  
Biomedical Literature ◽  
Cochrane Central Register ◽  
Patients With Cancer ◽  
General Quality ◽  
The Impact

Abstract Objective To assess the impact of informing diagnosis and disease status on the quality of life in patients with cancer Method We searched the follow databases, Pubmed, CENTRAL(Cochrane Central Register of Controlled Trials), PsycINFO, WEB OF SCIENCE, Embase, CBM (Chinese Biomedical Literature database), WANFANG database (Chinese Medicine Premier), and CNKI (China National Knowledge Infrastructure). And the terms used are as follows: neoplasm, cancer, tumour, tumor, carcinoma, disclosure, truth telling, breaking bad news, knowledge, knowing, awareness, quality of life, QOL. Pairs of reviewers independently screened documents and extracted the data. Meta-analysis was conducted by Revman 5.0 software. Results There were 11740 records retrieved from databases and 23 studies were included finally. Meta-analysis of informed and uniformed cancer patients revealed no differences in both the general quality of life and symptoms of fatigue, pain, dyspnea, insomnia, appetite loss and diarrhea (P>0.05). Additionally, no difference in physical function, role function, cognitive activity and emotional function between the above 2 groups(P>0.05) were found. On the vitality area, the patients who were totally informed about their diagnosis had higher vitality than the uniformed patients. However, patients aware about their illnesses seemed to get lower scores in social function. Between the partly informed of the diagnosis and uninformed cancer patients, there were no differences in general quality of life, function domains and disease-related symptoms (P>0.05). Conclusion Informing the cancer patients their diagnosis may not have a bad effect on their quality of life. PROSPERO registration number CRD42017060073.

scholarly journals Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes

BMJ Open ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. e033161
Author(s):  
Bin Qin ◽  
Guangsu Huang ◽  
Qian Yang ◽  
Mingjun Zhao ◽  
Hong Chen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Anxiety Disorder ◽  
Functional Status ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Generalised Anxiety Disorder ◽  
Multiple Doses

ObjectivesThe aim of this study was to investigate the efficacy, tolerability, safety, and impact on quality of life (QoL) and functional status of vortioxetine treatment for patients with generalised anxiety disorder (GAD) by performing a meta-analysis of randomised controlled trials (RCTs).DesignSystematic review and meta-analysis.Data sourcesData mining was conducted in January 2019 across PubMed, EMBASE, PsycINFO, Cochrane Central Register of Controlled Trials Cochrane Library, Web of science and ClinicalTrials.gov.Eligibility criteria for selecting studiesAll published RCTs, which assessed the effect of vortioxetine treatment for patients with GAD when compared with a placebo group, were included.Data extraction and synthesisRelevant data were extracted and synthesised narratively. Results were expressed as standardised mean differences or ORs with 95% CIs.ResultsOur meta-analysis showed that multiple doses (2.5, 5 and 10 mg/day) of vortioxetine did not significantly improve the response rates, compared with placebo (OR 1.16, 95% CI 0.84 to 1.60, p=0.38; OR 1.41, 95% CI 0.82 to 2.41, p=0.21; and OR 1.05, 95% CI 0.76 to 1.46, p=0.75). Moreover, there was no statistically significant difference regarding the remission rates, discontinuation for any reason rates, discontinuation due to adverse events rates, Short-Form 36 Health Survey scores or Sheehan Disability Scale scores between administration of multiple doses (2.5, 5 and 10 mg/day) of vortioxetine and placebo.ConclusionsAlthough our results suggest that vortioxetine did not improve the GAD symptoms, QoL and functional status impairment of patients with GAD, it was safe and well tolerated. Clinicians should interpret and translate our data with caution, as the meta-analysis was based on a limited number of RCTs.

scholarly journals The impact of informing diagnosis on quality of life in patients with cancer: A systematic review and meta-analysis

2020 ◽  
Author(s):  
Miao Wan ◽  
Xianggui Luo ◽  
Louis.B NDZANA MVOGO ◽  
Juan Wang ◽  
Chen Chang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Cognitive Activity ◽  
Biomedical Literature ◽  
Cochrane Central Register ◽  
Patients With Cancer ◽  
General Quality ◽  
The Impact

Abstract Objective To assess the impact of informing diagnosis and disease status on the quality of life in patients with cancer Method We searched the follow databases, Pubmed, CENTRAL(Cochrane Central Register of Controlled Trials), PsycINFO, WEB OF SCIENCE, Embase, CBM (Chinese Biomedical Literature database), WANFANG database (Chinese Medicine Premier), and CNKI (China National Knowledge Infrastructure). And the terms used are as follows: neoplasm, cancer, tumour, tumor, carcinoma, disclosure, truth telling, breaking bad news, knowledge, knowing, awareness, quality of life, QOL. Pairs of reviewers independently screened documents and extracted the data. Meta-analysis was conducted by Revman 5.0 software. Results There were 11740 records retrieved from databases and 23 studies were included finally. Meta-analysis of informed and uniformed cancer patients revealed no differences in both the general quality of life and symptoms of fatigue, pain, dyspnea, insomnia, appetite loss and diarrhea (P>0.05). Additionally, no difference in physical function, role function, cognitive activity and emotional function between the above 2 groups(P>0.05) were found. On the vitality area, the patients who were totally informed about their diagnosis had higher vitality than the uniformed patients. However, patients aware about their illnesses seemed to get lower scores in social function. Between the partly informed of the diagnosis and uninformed cancer patients, there were no differences in general quality of life, function domains and disease-related symptoms (P>0.05). Conclusion Informing the cancer patients their diagnosis may not have a bad effect on their quality of life. PROSPERO registration number CRD42017060073.

scholarly journals Arts Therapies for Anxiety, Depression, and Quality of Life in Breast Cancer Patients: A Systematic Review and Meta-Analysis

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Katja Boehm ◽  
Holger Cramer ◽  
Thomas Staroszynski ◽  
Thomas Ostermann
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Breast Cancer Patients ◽  
Dance Movement ◽  
Beneficial Effects

Background. Breast cancer is one of the most common types of cancer. However, only a few trials assess the effects of arts therapies.Material and Methods. We searched the Cochrane Central Register of Controlled Trials, PubMed, and Google Scholar from their start date to January 2012. We handsearched reference lists and contacted experts. All randomized controlled trials, quasi-randomized trials, and controlled clinical trials of art interventions in breast cancer patients were included. Data were extracted and risk of bias was assessed. Meta-analyses were performed using standardized mean differences.Results. Thirteen trials with a total of 606 patients were included. Arts therapies comprised music therapy interventions, various types of art therapy, and dance/movement therapies. The methodological quality ranged from poor to high quality with the majority scoring 3 of 4 points on the Jadad scale. Results suggest that arts therapies seem to positively affect patients’ anxiety (standardized mean difference: −1.10; 95%, confidence interval: −1.40 to −0.80) but not depression or quality of life. No conclusion could be drawn regarding the effects of arts therapy on pain, functional assessment, coping, and mood states.Discussion. Our review indicates that arts interventions may have beneficial effects on anxiety in patients with breast cancer.

scholarly journals Effects of exercise-based pulmonary rehabilitation on adults with asthma: a systematic review and meta-analysis

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Zhenzhen Feng ◽  
Jiajia Wang ◽  
Yang Xie ◽  
Jiansheng Li
Keyword(s):  
Quality Of Life ◽  
Pulmonary Rehabilitation ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Control Group ◽  
Life Questionnaire ◽  
Asthma Control Questionnaire ◽  
Clinical Trial Registration ◽  
Domain Scores

Abstract Background Pulmonary rehabilitation (PR) has been proposed as an effective method for many respiratory diseases. However, the effects of exercise-based PR on asthma are currently inconclusive. This review aimed to investigate the effects of exercise-based PR on adults with asthma. Methods The PubMed, Embase, Cochrane Library, Web of Science, International Clinical Trials Registry Platform and ClinicalTrials.gov databases were searched from inception to 31 July 2019 without language restriction. Randomized controlled trials (RCTs) investigating the effects of exercise-based PR on adults with asthma were included. Study selection, data extraction and risk of bias assessment were performed by two investigators independently. Meta-analysis was conducted by RevMan software (version 5.3). Evidence quality was rated by the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Results Ten literatures from nine studies (n = 418 patients) were identified. Asthma quality of life questionnaire total scores (MD = 0.39, 95% CI: 0.02 to 0.76) improved significantly in the experimental group compared to control group, including activity domain scores (MD = 0.58, 95% CI: 0.21 to 0.94), symptom domain scores (MD = 0.52, 95% CI: 0.19 to 0.85), emotion domain scores (MD = 0.53, 95% CI: − 0.03 to 1.09) and environment domain scores (MD = 0.56, 95% CI: 0.00 to 1.11). Both the 6-min walk distance (MD = 34.09, 95% CI: 2.51 to 65.66) and maximum oxygen uptake (MD = 4.45, 95% CI: 3.32 to 5.58) significantly improved. However, improvements in asthma control questionnaire scores (MD = − 0.25, 95% CI: − 0.51 to 0.02) and asthma symptom-free days (MD = 3.35, 95% CI: − 0.21 to 6.90) were not significant. Moreover, there was no significant improvement (MD = 0.10, 95% CI: − 0.08 to 0.29) in forced expiratory volume in 1 s. Nonetheless, improvements in forced vital capacity (MD = 0.23, 95% CI: 0.08 to 0.38) and peak expiratory flow (MD = 0.39, 95% CI: 0.21 to 0.57) were significant. Conclusions Exercise-based PR may improve quality of life, exercise tolerance and some aspects of pulmonary function in adults with asthma and can be considered a supplementary therapy. RCTs of high quality and large sample sizes are required. Clinical trial registration: The review was registered with PROSPERO (The website is https://www.crd.york.ac.uk/prospero/, and the ID is CRD42019147107).

scholarly journals The Effectiveness of Acupuncture in Management of Functional Constipation: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-17
Author(s):  
Lu Wang ◽  
Mingmin Xu ◽  
Qianhua Zheng ◽  
Wei Zhang ◽  
Ying Li
Keyword(s):  
Quality Of Life ◽  
Meta Analysis ◽  
Safety Evaluation ◽  
Functional Constipation ◽  
Responder Rate ◽  
Current Evidence ◽  
Cochrane Library ◽  
China National Knowledge Infrastructure ◽  
Increased Risk

Objective. The purpose of this study was to assess the effectiveness and safety of acupuncture for functional constipation (FC). Methods. A rigorous literature search was performed in English (PubMed, Web of Science, the Cochrane Library, and EMBASE) and Chinese (China National Knowledge Infrastructure (CNKI), Chinese Biological Medical (CBM), Wanfang database, and China Science and Technology Journal (VIP)) electronic databases from their inception to October 2019. Included randomized controlled trials (RCTs) compared acupuncture therapy with sham acupuncture or pharmacological therapies. The outcome measures were evaluated, including the primary outcome of complete spontaneous bowel movement (CSBM) and secondary outcomes of Bristol Stool Form Scale (BSFS), constipation symptoms scores (CSS), responder rate, the Patient Assessment of Constipation Quality of Life (PAC-QOL) questionnaire, and safety evaluation. Meta-analysis was performed by using RevMan5.3. Results. The merged data of 28 RCTs with 3525 participants indicated that acupuncture may be efficient for FC by increasing CSBMs (p<0.00001; MD = 0.84 [95% CI, 0.65 to 1.03]; I2 = 0%) and improving constipation symptoms (p=0.03; SMD = −0.4 [95% CI, −0.78 to −0.03]; I2 = 74%), stool formation (p<0.00001; MD = 0.24 [95% CI, 0.15 to 0.34]; I2 = 0%), quality of life (p<0.00001; N = 1, MD = −0.33 [95% CI, −0.45 to −0.21]), and responder rates (p=0.02; RR = 2.16; [95% CI, 1.1 to 4.24]; I2 = 69%) compared with the effects of sham treatment. No increased risk of adverse events was observed (p=0.44; RR = 1.18; [95% CI, 0.77 to 1.81]; I2 = 0%). With regard to medication comparisons, the pooled data indicated that acupuncture was more effective in increasing CSBMs (p=0.004; MD = 0.53 [95% CI, 0.17 to 0.88]; I2 = 88%) and improving patients’ quality of life (p<0.00001; SMD = −0.73 [95% CI, −1.02 to −0.44]; I2 = 64%), with high heterogeneity. However, there were no significant differences in responder rate (p=0.12; RR = 1.31; [95% CI, 0.94 to 1.82]; I2 = 53%), BSFS (p=0.5; MD = 0.17 [95% CI, −0.33 to 0.68]; I2 = 93%), or CSS (p=0.05; SMD = −0.62 [95% CI, −1.23 to −0.01]; I2 = 89%). Regarding safety evaluation, acupuncture was safer than medications (p<0.0001; RR = 0.3; [95% CI, 0.18 to 0.52]; I2 = 30%). Conclusions. Current evidence suggests that acupuncture is an efficient and safe treatment for FC. Acupuncture increased stool frequency, improved stool formation, alleviated constipation symptoms, and improved quality of life. However, the evidence quality was relatively low and the relationship between acupuncture and drugs is not clear. More high-quality trials are recommended in the future. PROSPERO registration number: CRD42019143347.

Sign in / Sign up

Export Citation Format

Share Document